Company Description
Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States.
Its oncology pipeline includes CM24, a humanized monoclonal antibody that blocks the interactions of carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 2 clinical trial for the treatment of pancreatic ductal adenocarcinoma; NT219, a small molecule that targets and inhibits insulin receptor substrate 1 and 2, and signal transducer and activator of transcription, which is in Phase 1/2 clinical trials for the treatment recurrent and/or metastatic squamous cell carcinoma of the head and neck cancer or colorectal adenocarcinoma; and IM1240, a multi-valent antibody designed to activate anti-tumoral immune response against 5T4-positive tumors, which is in preclinical stage.
The company has collaboration agreement with Bristol Myers Squibb Company to evaluate the combination of CM24 with the PD-1 inhibitor nivolumab in addition to chemotherapy.
The company was formerly known as Kitov Pharma Ltd and changed its name to Purple Biotech Ltd. in December 2020.
The company is headquartered in Rehovot, Israel.
| Country | Israel |
| Founded | 2010 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 20 |
| CEO | Gil Efron CPA, M.A. |
Contact Details
Address: 4 Oppenheimer Street, Science Park Rehovot, L3 7670104 Israel | |
| Phone | 97239333121 |
| Website | purple-biotech.com |
Stock Details
| Ticker Symbol | PPBT |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001614744 |
| CUSIP Number | 74638P109 |
| ISIN Number | US74638P1093 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Gil Efron CPA, M.A. | Chief Executive Officer |
| Dr. Michael Schickler Ph.D. | Head of Clinical and Regulatory Affairs |
| Lior Fhima CPA, M.B.A. | Chief Financial Officer |
| Ido Morpurgo B.Sc., L.L.M. | Vice President of Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 2, 2024 | EFFECT | Notice of Effectiveness |
| Mar 28, 2024 | POS AM | Post-Effective amendments for registration statement |
| Mar 28, 2024 | 6-K | Report of foreign issuer |
| Mar 14, 2024 | 6-K | Report of foreign issuer |
| Mar 6, 2024 | 6-K | Report of foreign issuer |
| Mar 5, 2024 | 20-F | Annual and transition report of foreign private issuers |
| Mar 5, 2024 | 6-K | Report of foreign issuer |
| Feb 27, 2024 | 6-K | Report of foreign issuer |
| Feb 14, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Feb 13, 2024 | 6-K | Report of foreign issuer |